NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway

Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity

(2020) Yi Huang et al.   NATURE CELL BIOLOGY

The Landscape of Targeted Therapies in TNBC

(2020) Elena Vagia et al.   Cancers

Growth of breast cancer cells by leptin is mediated via activation of the inflammasome: Critical roles of estrogen receptor signaling and reactive oxygen species production

(2019) Pawan Kumar Raut et al.   BIOCHEMICAL PHARMACOLOGY

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

(2019) Gloria V. Echeverria et al.   Science Translational Medicine

First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

(2019) Anna Capasso et al.   MOLECULAR CANCER THERAPEUTICS

Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling

(2019) Dattatrya Shetti et al.   Cells

Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge

(2019) Nedeljković et al.   Cells

Combination of Doxorubicin with Gemcitabine-Incorporated GQuadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells

(2019) Mili Joshi et al.   JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY

Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion

(2019) Lingling Si et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

MiR‐6838‐5p suppresses cell metastasis and the EMT process in triple‐negative breast cancer by targeting WNT3A to inhibit the Wnt pathway

(2019) Guozhu Liu et al.   JOURNAL OF GENE MEDICINE

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer

(2018) J Zhang et al.   ANNALS OF ONCOLOGY

Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study

(2018) Ryusei Matsuyama et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Gemcitabine reduces recurrence

(2018) Louise Stone   Nature Reviews Urology

NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells

(2018) Xia Ma et al.   PLoS One

Upregulated IQUB promotes cell proliferation and migration via activating Akt/GSK3β/β-catenin signaling pathway in breast cancer

(2018) Kai Li et al.   Cancer Medicine

The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer

(2018) Yanfei Jia et al.   ONCOGENE

The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma

(2017) Xiaodong Feng et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β

(2017) Benjamin Weichand et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Triple-negative breast cancer and the potential for targeted therapy

(2017) Jing-Ru Jhan et al.   PHARMACOGENOMICS

Cancer cells induce interleukin-22 production from memory CD4+T cells via interleukin-1 to promote tumor growth

(2017) Cornelia Voigt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammasomes and Cancer

(2017) Rajendra Karki et al.   Cancer Immunology Research

Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition

(2016) Shweta Shrivastava et al.   BIOFACTORS

EMT: 2016

(2016) M. Angela Nieto et al.   CELL

Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone

(2016) Myeongjin Jeon et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

(2015) Xi-Chun Hu et al.   LANCET ONCOLOGY

Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning

(2015) Stephanie N. Dorman et al.   Molecular Oncology

Breast cancer

(2015) Chris Woolston   NATURE

NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells

(2015) Steven W Paugh et al.   NATURE GENETICS

MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer

(2015) Zhen-Hua Wu et al.   TUMOR BIOLOGY

β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells

(2015) Jinhua Xu et al.   PLoS One

Subtyping of triple-negative breast cancer: Implications for therapy

(2014) Vandana G. Abramson et al.   CANCER

TLR-induced PAI-2 expression suppresses IL-1  processing via increasing autophagy and NLRP3 degradation

(2013) S.-Y. Chuang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pseudogenes as Weaknesses of ACTB (Actb) and GAPDH (Gapdh) Used as Reference Genes in Reverse Transcription and Polymerase Chain Reactions

(2012) Yuan Sun et al.   PLoS One

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE